TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
REPL

Replimune Group Inc

Healthcare · Biotechnology

13.10$ +1.6% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

Replimune Group Inc (REPL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 0.0 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement REPL
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
0.0 0.0 4.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0
0.7 0.7 0.7 0.7 0.9 1.0 0.8 1.7 1.6 1.6
-0.7 -0.7 3.4 -0.7 -0.9 -1.0 -0.8 -1.7 -1.6 -1.6
49 43 43 43 43 48 55 58 58 53 52 49 213
15 14 16 14 15 18 25 33 26 19 21 19 85
64 57 59 57 59 66 79 90 84 72 73 68 298
-64 -57 -59 -57 -59 -66 -80 -90 -84 -72 -73 -68 -298
1.5 1.6 2.0 2.0 2.0 2.0 2.0 2.0 0.5 2.0 4.4 2.6 9.5
-60 -51 -55 -54 -53 -66 -75 -87 -83 -71 -73 -70 -298
-0.2 0.5 -0.1 -0.4 -0.4 0.6 -0.7 -0.4 -0.3 -0.2 -0.3
-60 -51 -55 -54 -53 -66 -74 -87 -83 -71 -73 -70 -297
-63 -55 -55 -56 -58 -65 -72 -89 -82 -68 -75 -66 -291

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?